Indigo Naturalis in Inflammatory Bowel Disease: mechanisms of action and insights from clinical trials
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study investigates the therapeutic potential of Indigo Naturalis (IN) in treating a Inflammatory Bowel Disease (IBD). The objective is to comprehensively examine the effects and pharmacological mechanisms of IN on IBD, assessing its potential as an novel treatment for IBD. Analysis of 11 selected papers is conducted to understand the effects of IN, focusing on compounds like indirubin, isatin, indigo, and tryptanthrin. This study evaluates their impact on Disease Activity Index (DAI) score, colon length, mucosal damage, and macrophage infiltration in Dextran Sulfate Sodium (DSS)-induced colitis mice. Additionally, It investigate into the anti-inflammatory mechanisms, including Aryl hydrocarbon Receptor (AhR) pathway activation, Nuclear Factor kappa B (NF-κB)/nod-like receptor family pyrin domain containing 3 (NLRP3)/Interleukin 1 beta (IL-1β) inhibition, and modulation of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MYD88)/NF-κB and Mitogen Activated Protein Kinase (MAPK) pathways. Immunomodulatory effects on T helper 17 (Th17)/regulatory T cell (Treg cell) balance and Glycogen synthase kinase-3 beta (GSK3-β) expression are also explored. Furthermore, the study addresses the role of IN in restoring intestinal microbiota diversity, reducing pathogenic bacteria, and increasing beneficial bacteria. The findings reveal that IN, particularly indirubin and indigo, demonstrates significant improvements in DAI score, colon length, mucosal damage, and macrophage infiltration in DSS-induced colitis mice. The anti-inflammatory effects are attributed to the activation of the AhR pathway, inhibition of inflammatory pathways, and modulation of immune responses. These results exhibit the potential of IN in IBD treatment. Notably, the restoration of intestinal microbiota diversity and balance further supports its efficacy. IN emerges as a promising and effective treatment for IBD, demonstrating anti-inflammatory effects and positive outcomes in preclinical studies. However, potential side effects necessitate further investigation for safe therapeutic development. The study underscores the need for future research to explore a broader range of active ingredients in IN to enhance therapeutic efficacy and safety.
Abstract
This study investigates the therapeutic potential of Indigo Naturalis (IN) in treating a Inflammatory Bowel Disease (IBD). The objective is to comprehensively examine the effects and pharmacological mechanisms of IN on IBD, assessing its potential as an novel treatment for IBD. Analysis of 11 selected papers is conducted to understand the effects of IN, focusing on compounds like indirubin, isatin, indigo, and tryptanthrin. This study evaluates their impact on Disease Activity Index (DAI) score, colon length, mucosal damage, and macrophage infiltration in Dextran Sulfate Sodium (DSS)-induced colitis mice. Additionally, It investigate into the anti-inflammatory mechanisms, including Aryl hydrocarbon Receptor (AhR) pathway activation, Nuclear Factor kappa B (NF-κB)/nod-like receptor family pyrin domain containing 3 (NLRP3)/Interleukin 1 beta (IL-1β) inhibition, and modulation of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MYD88)/NF-κB and Mitogen Activated Protein Kinase (MAPK) pathways. Immunomodulatory effects on T helper 17 (Th17)/regulatory T cell (Treg cell) balance and Glycogen synthase kinase-3 beta (GSK3-β) expression are also explored. Furthermore, the study addresses the role of IN in restoring intestinal microbiota diversity, reducing pathogenic bacteria, and increasing beneficial bacteria. The findings reveal that IN, particularly indirubin and indigo, demonstrates significant improvements in DAI score, colon length, mucosal damage, and macrophage infiltration in DSS-induced colitis mice. The anti-inflammatory effects are attributed to the activation of the AhR pathway, inhibition of inflammatory pathways, and modulation of immune responses. These results exhibit the potential of IN in IBD treatment. Notably, the restoration of intestinal microbiota diversity and balance further supports its efficacy. IN emerges as a promising and effective treatment for IBD, demonstrating anti-inflammatory effects and positive outcomes in preclinical studies. However, potential side effects necessitate further investigation for safe therapeutic development. The study underscores the need for future research to explore a broader range of active ingredients in IN to enhance therapeutic efficacy and safety.
참고문헌 (62)
- Le Berre C, "Ulcerative colitis", Lancet, 402(10401), pp.571~584 (2023)
- Pastorelli L, "Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation : lessons learned from animal models and human genetics", Front Immunol, 4, pp.280~ (2013)
- Kostic AD, "The microbiome in inflammatory bowel disease : current status and the future ahead", Gastroenterology, 146(6), pp.1489~1499 (2014)
- Yang Y, "Bergamot polysaccharides relieve DSS-induced ulcerative colitis via regulating the gut microbiota and metabolites", Int J Biol Macromol, 253(Pt 7), pp.127335~ (2023)
- Ordás I, "Ulcerative colitis", Lancet, 380(9853), pp.1606~1619 (2012)
- Abraham C, "Inflammatory bowel disease", N Engl J Med, 361(21), pp.2066~2078 (2009)
- Feuerstein JD, "Ulcerative colitis", Mayo Clin Proc, 94(7), pp.1357~1373 (2019)
- Park J, "Incidence and prevalence of inflammatory bowel disease across Asia", Yonsei Med J, 62(2), pp.99~108 (2021)
- da Silva BC, "Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis", World J Gastroenterol, 20(28), pp.9458~9467 (2014)
- Sun Q, "A comprehensive review of the chemistry, pharmacokinetics, pharmacology, clinical applications, adverse events, and quality control of indigo naturalis", Front Pharmacol, 12, pp.664022~ (2021)
- Chen LH, "Extraction of indirubin from indigo naturalis and its antioxidant activity", J Jishou Univ(Nat Sci Ed), 34(1), pp.72~76 (2013)
- Jie C, "Indirubin, a bisindole alkaloid from Isatis indigotica, reduces H1N1 susceptibility in stressed mice by regulating MAVS signaling", Oncotarget, 8(62), pp.105615~105629 (2017)
- Chang SJ, "Antiviral activity of Isatis indigotica extract and its derived indirubin against Japanese encephalitis virus", Evid Based Complement Alternat Med, 2012, pp.925830~ (2012)
- Mak NK, "Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells", Biochem Pharmacol, 67(1), pp.167~174 (2004)
- Lin CW, "Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds", Antiviral Res, 68(1), pp.36~42 (2005)
- Farias-Silva E, "Antioxidant activity of indigo and its preventive effect against ethanol-induced DNA damage in rat gastric mucosa", Planta Med, 73(12), pp.1241~1246 (2007)
- Tsai YC, "Antiviral action of tryptanthrin isolated from Strobilanthes cusia leaf against human coronavirus NL63", Biomolecules, 10(3), pp.366~ (2020)
- Chiang YR, "An in vitro study of the antimicrobial effects of indigo naturalis prepared from Strobilanthes formosanus Moore", Molecules, 18(11), pp.14381~14396 (2013)
- Plitzko I, "Composition of Indigo naturalis", Planta Med, 75(8), pp.860~863 (2009)
- Chang HN, "Indigo naturalis and its component tryptanthrin exert antiangiogenic effect by arresting cell cycle and inhibiting Akt and FAK signaling in human vascular endothelial cells", J Ethnopharmacol, 174, pp.474~481 (2015)
- Chassaing B, "Dextran sulfate sodium(DSS)-induced colitis in mice", Curr Protoc Immunol, 104, pp.15.25~ (2014)
- Shimizu T, "Indigo enhances wound healing activity of Caco-2 cells via activation of the aryl hydrocarbon receptor", J Nat Med, 75(4), pp.833~839 (2021)
- Liu Z, "Transcriptomic analysis reveals the regulatory mechanism underlying the indirubin-mediated amelioration of dextran sulfate sodium-induced colitis in mice", Pharm Biol, 61(1), pp.1082~1093 (2023)
- Karin M, "NF-kappaB in cancer : from innocent bystander to major culprit", Nat Rev Cancer, 2(4), pp.301~310 (2002)
- Lu YC, "LPS", TLR4 signal transduction pathway, 2008, pp.42(2), 145~151
- Yang QY, "Exploring the mechanism of indigo naturalis in the treatment of ulcerative colitis based on TLR4", MyD88, Front Pharmacol, pp.2021, 12[DOI]
- Gao W, "The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice", Biochem Cell Biol, 96(5), pp.636~645 (2018)
- He G, "NF-κB and STAT3-key players in liver inflammation and cancer", Cell Res, 21(1), pp.159~168 (2011)
- Wang Z, "Tryptanthrin protects mice against dextran sulfate sodiuminduced colitis through inhibition of TNF-α", NF-κB and IL-6, Molecules, pp.2018, 23(5)[DOI]
- Travis MA, "TGF-β activation and function in immunity", Annu Rev Immunol, 32, pp.51~82 (2014)
- Travis MA, "Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice", Nature, 449(7160), pp.361~365 (2007)
- Zhang T, "Indirubin regulates T cell differentiation by promoting αVβ8 expression in bone marrow-derived dendritic cells to alleviate inflammatory bowel disease", Phytother Res, 37(1), pp.89~100 (2023)
- Lee GR, "The balance of Th17 versus Treg cells in autoimmunity", Int J Mol Sci, 19(3), pp.730~ (2018)
- Chen Z, "FOXP3 and RORγt : transcriptional regulation of Treg and Th17", Int Immunopharmacol, 11(5), pp.536~542 (2011)
- Xiao HT, "Indigo naturalis suppresses colonic oxidative stress and Th1", Th17 responses of DSS-induced colitis in mice, 2019, pp.2019, 9480945~
- Beurel E, "Innate and adaptive immune responses regulated by glycogen synthase kinase-3(GSK3)", Trends Immunol, 31(1), pp.24~31 (2010)
- Hofmann C, "Glycogen synthase kinase 3-β : a master regulator of toll-like receptor-mediated chronic intestinal inflammation", Inflamm Bowel Dis, 16(11), pp.1850~1858 (2010)
- Beurel E, "Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells", J Immunol, 186(3), pp.1391~1398 (2011)
- Graham JA, "Suppressive regulatory T cell activity is potentiated by glycogen synthase kinase 3{beta} inhibition", J Biol Chem, 285(43), pp.32852~32859 (2010)
- Yue LI, "Efficacy of active ingredients in Qingdai on ulcerative colitis : a network pharmacology-based evaluation", J Tradit Chin Med, 43(1), pp.124~133 (2023)
- Morgan XC, "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment", Genome Biol, 13(9), pp.R79~ (2012)
- Akhtar M, "Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation", Anim Nutr, 8, pp.350~360 (2021)
- Shin Y, "Roles of short-chain fatty acids in inflammatory bowel disease", Nutrients, 15(20), pp.4466~ (2023)
- Lee C, "Disturbance of lipid metabolism in germ-free mice transplanted with gut microbiota of DSS-induced colitis mice", PLoS One, 18(2), pp.e0280850~ (2023)
- Kabat AM, "Modulation of immune development and function by intestinal microbiota", Trends Immunol, 35(11), pp.507~517 (2014)
- Yan JB, "The function and role of the Th17", Treg cell balance in inflammatory bowel disease, 2020, pp.2020, 8813558~
- Xie J, "Combination therapy with indigo and indirubin for ulcerative colitis via reinforcing intestinal barrier function", Oxid Med Cell Longev, 2023, pp.2894695~ (2023)
- Sun Z, "Indigo naturalis alleviates dextran sulfate sodium-induced colitis in rats via altering gut microbiota", Front Microbiol, 11, pp.731~ (2020)
- Liang YN, "Indigo naturalis ameliorates dextran sulfate sodium-induced colitis in mice by modulating the intestinal microbiota community", Molecules, 24(22), pp.4086~ (2019)
- Ben-Horin S, "Curcumin-QingDai combination for patients with active ulcerative colitis : a randomized, double-blinded, placebocontrolled trial", Clin Gastroenterol Hepatol, 22(2), pp.347~356 (2024)
- Uchiyama K, "Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis : an investigator-initiated multicenter double-blind clinical trial", PLoS One, 15(11), pp.e0241337~ (2020)
- Naganuma M, "Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis", Gastroenterology, 154(4), pp.935~947 (2018)
- Lin YK, "Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment : a randomized, double-blind, dosage-controlled trial", Br J Dermatol, 178(1), pp.124~131 (2018)
- Lin YK, "Efficacy and safety of indigo naturalis ointment in treating atopic dermatitis : a randomized clinical trial", J Ethnopharmacol, 250, pp.112477~ (2020)
- Iacucci M, "Mesalazine in inflammatory bowel disease : a trendy topic once again?", Can J Gastroenterol, 24(2), pp.127~133 (2010)
- Baker DE, "Safety of balsalazide therapy in the treatment of inflammatory bowel disease", Rev Gastroenterol Disord, 5(3), pp.135~141 (2005)
- Li J, "Orally administrated olsalazineloaded multilayer pectin", chitosan, Biomacromolecules, pp.2023, 24(5)[DOI]
- Kubota K, "Dramatically improved severe pulmonary arterial hypertension caused by Qing-Dai(Chinese herbal drug)for ulcerative colitis", Int Heart J, 64(2), pp.316~320 (2023)
- Inoue Y, "Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis", J Cardiol Cases, 27(5), pp.218~221 (2023)
- Misumi K, "Development of pulmonary arterial hypertension in a patient treated with Qing-Dai(Chinese herbal medicine)", Intern Med, 58(3), pp.395~399 (2019)
- Abenhaim L, "Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group", N Engl J Med, 335(9), pp.609~616 (1996)
- Zhang Q, "Psoriasis treatment using indigo naturalis : progress and strategy", J Ethnopharmacol, 297, pp.115522~ (2022)